Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Article first published online: 25 MAY 2010
© 2010 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 32, Issue 4, pages 522–528, August 2010
How to Cite
Gies, N., Kroeker, K. I., Wong, K. and Fedorak, R. N. (2010), Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Alimentary Pharmacology & Therapeutics, 32: 522–528. doi: 10.1111/j.1365-2036.2010.04380.x
- Issue published online: 14 JUL 2010
- Article first published online: 25 MAY 2010
- Publication data Submitted 1 March 2010 First decision 23 March 2010 Resubmitted 19 May 2010 Accepted 21 May 2010 Epub Accepted Article 25 May 2010
Aliment Pharmacol Ther 2010; 32: 522–528
Background Randomized, controlled trials have demonstrated that anti-TNF agents are efficacious in inducing remission in cases of Crohn’s disease and ulcerative colitis. However, response rates for anti-TNF agents in ‘real life’ clinical practice are less well-defined.
Aims To examine the response rates and long-term outcomes of infliximab and adalimumab treatment for out-patients with ulcerative colitis and to study the variables associated with response rates.
Methods In a prospective study, a single-centre out-patient cohort was treated and followed up according to a structured protocol of clinical care. Response to treatment was assessed using a physician’s global assessment that focused on normalization of bowel frequency, absence of blood with defecation and tapering of corticosteroids to zero.
Results Fifty-three ulcerative colitis patients were included in the study. Responses to induction therapy were 96.4% (27/28) for infliximab and 80% (20/25) for adalimumab (P = 0.0889). Responses to maintenance therapy were similar: infliximab 77.8% (14/18) and adalimumab 70.0% (14/20) (P = 0.7190). Multivariate analyses of the induction and maintenance responses did not reveal confounding elements. No new safety signals were identified.
Conclusions This long-term follow-up of a single-centre cohort of ulcerative colitis patients demonstrates that ‘real-life’ out-patient treatment with infliximab and adalimumab is effective in induction and maintenance of response.